18.32
-0.35 (-1.87%)
| Previous Close | 18.67 |
| Volume | 1,533,600 |
| Price / Earnings (Forward) | 20.38 |
| Price / Sales | 2.70 |
| Price / Book | 2.34 |
| 52 Weeks Range |
| Profit Margin | 22.97% |
| Operating Margin (TTM) | 7.90% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 18.70% |
| Quarterly Earnings Growth (YOY) | 14.70% |
| Total Debt/Equity (MRQ) | 7.32% |
| Current Ratio (MRQ) | 2.88 |
| Operating Cash Flow (TTM) | 148.96 M |
| Levered Free Cash Flow (TTM) | 19.27 M |
| Return on Assets (TTM) | 5.56% |
| Return on Equity (TTM) | 37.24% |
News Mood
- What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
- Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
AIStockmoo Score
| Value 30% | 1.2 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Priced high for its earnings growth. info | |
| The price implies earnings growth of -4.4% a year; the business can fund about 15.0% a year. info | |
| Valuation History info | NA |
| Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Timing 30% | -1.9 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Recent bullish reversal pattern: Bullish engulfing. info | |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | -0.7 |
| Insider Activity info | NA |
| Institutions net -0.57% of shares in their latest 13F filings: 216 holders increased, 159 decreased (quarter to 30 Sep 2026). info | |
| Short interest -14.6% from 31 Aug to 30 Oct 2026, 5.9 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. info | |
| Short-term momentum falling. info | |
| Price is between support and resistance. info | |
| Final Score | -0.31 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ACADIA Pharmaceuticals Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ACAD | - | - | - | 2.34 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| COGT | - | - | - | 11.00 |
| CYTK | - | - | - | - |
Select this tab to load the latest available analysis.
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.57% |
| % Held by Institutions | 104.46% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 106.56%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 216 | 14,490,539 |
| Decreased | 159 | 14,311,770 |
| New | 66 | 2,351,806 |
| Sold out | 59 | 3,514,997 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 8,317,392 | 5.9 |
| 15 Oct 2026 | 9,094,151 | 4.6 |
| 30 Sep 2026 | 8,275,918 | 2.9 |
| 15 Sep 2026 | 9,666,972 | 7.2 |
| 31 Aug 2026 | 9,739,720 | 6.9 |
| 14 Aug 2026 | 9,478,912 | 4.5 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SAN DIEGO, November 17, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the… |
| 16 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
SAN DIEGO, November 16, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the… |
| 10 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Fell While Sales Rose
Acadia Pharmaceuticals ended Q3 2026 touting a revenue beat, stronger Daybue and Nuplazid sales, and fresh guidance pointing to full year revenue between US$1.26b and US$1.3b. Holding Acadia Pharmaceuticals from the start of the year would have meant a 37.2% loss, including dividends. If you had… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
SAN DIEGO, November 10, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No.… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
Acadia Pharmaceuticals shares have dropped sharply so far in 2026, raising a clear question for investors who watch valuation closely. With the stock under pressure and earnings in focus, the issue is whether today's price fairly reflects what the business is currently earning. The share price is… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
Acadia Pharmaceuticals (ACAD) just paired fresh quarterly results with a guidance tweak and new Alzheimer’s trial data, giving investors several moving parts to assess at the same time. The reaction has been harsh. Acadia Pharmaceuticals’ share price has fallen about 22% over the last day and is… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
SAN DIEGO, Calif., November 09, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November… |
| 05 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
Acadia Pharmaceuticals (ACAD) reported Q3 results underpinned by continued Daybue growth and steady… |
| 05 Nov 2026 | Yahoo Finance |
ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ...
ACADIA Pharmaceuticals Inc (ACAD) posted $342 million in quarterly revenue and lifted its Daybue outlook, even as the remlifanserin Phase 2 study narrowly missed statistical significance. |
| 04 Nov 2026 | Yahoo Finance |
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson’s disease psychosis drug NUPLAZID drove growth. The company raised its full-year DAYBUE sales out… |
| 04 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +63.16% and +2.22%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Acadia: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported third-quarter earnings of $53… |
| 04 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
SAN DIEGO, November 04, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026… |
| 29 Oct 2026 | Yahoo Finance |
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
SAN DIEGO, October 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. Greenwich Mean Time. |
| 28 Oct 2026 | Yahoo Finance |
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 21 Oct 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
SAN DIEGO, October 21, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on… |
| 21 Oct 2026 | Yahoo Finance |
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential. |
| 13 Oct 2026 | Yahoo Finance |
Top Midday Decliners
UBS downgraded Acadia Pharmaceuticals' (ACAD) shares one notch to neutral and set a $23 price target… |
| 13 Oct 2026 | Yahoo Finance |
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |